Generex Announces Presentations of Novel Vaccine Strategies

WORCESTER, Mass., Sept. 16 /PRNewswire/ -- Generex Biotechnology Corporation (NasdaqCM: GNBT; www.generex.com) today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).  The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.  Both were podium presentations given by Dr. Douglas Powell, Director of Immunobiology at Antigen Express.

At the Gene based Vaccines conference, the purpose of which was to analyze novel vaccine design and delivery methods in order to translate evidence into clinical success, the presentation Examining the different novel prime boost strategies and their applications for potential clinical use described the combined use of the Ii-Key hybrids developed at Antigen Express with DNA vaccines as a more potent means for stimulating immunity.  This immunization strategy has potential application both for better prevention of infectious diseases, like influenza, as well as for the treatment of chronic viral infections (e.g., HIV) and malignancies.  

The focus Dr. Powell's presentation at the Immunotherapeutics and Vaccine Summit, entitled Synthetic Peptide Vaccine for Pandemic Flu was on the Company's development of vaccines for influenza.  Clinical trials have been conducted on synthetic Ii-Key-modified peptides that are applicable to both the H5N1 and the 2009 H1N1 swine flu strains.  Synthetic vaccines offer clear advantages over traditional egg or cell culture-based vaccines in their design, manufacturing, and use.  The Company is continuing its work toward developing synthetic vaccines for both pandemic and seasonal influenza strains.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED